Fixed drug eruption related to sunitinib: a case report
Published Web Locationhttps://doi.org/10.5070/D3246040688
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor. It has been approved for the treatment of gastro-intestinal stromal tumor and advanced renal cell carcinoma. Fixed drug eruption related to sunitinib is a rare cutaneous adverse drug reaction.